Abstract
Parkinson’s disease (PD) is one of the most common age-related neurodegenerative disorders. Although predominantly a motor disorder, cognitive impairment and dementia are important features of PD, particularly in the later stages of the disease. However, the rate of cognitive decline varies widely among PD patients, and the genetic basis for this heterogeneity is incompletely understood. Here, we have analysed 3,964 clinically diagnosed PD cases to explore the genetic factors associated with rate of progression to PD dementia. Genome-wide survival analysis identified the APOE-ε4 allele as a major risk factor for the conversion to PD dementia, as well as three new loci, including the ApoE and APP receptor LRP1B. Biomarker analysis also implicates the amyloid pathway in PD dementia, suggesting that amyloid-targeting therapy may have an important role in preventing PDD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/huw-morris-lab/PDD_GWSS
Funding Statement
This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant number: ASAP-000478] through the Michael J. Fox Foundation for Parkinson’s Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright licence to all Author Accepted Manuscripts arising from this submission. This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Both TPD and OPDC cohorts are primarily funded and supported by Parkinson's UK and supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). The TPD study is also supported by NHS Greater Glasgow and Clyde. The OPDC cohort is also supported by the NIHR Oxford Biomedical Research Centre, based at the Oxford University Hospitals NHS Trust, and the University of Oxford. The DIGPD cohort is sponsored by Assistance Publique Hopitaux de Paris, funded by a grant from the French Ministry of Health (PHRC 2008, AOR0810) and a grant from the Agence Nationale de Securite et des Medicaments (ANSM–2013).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TPD has multi-centre research ethics approval from the West of Scotland Research Ethics Committee (REC reference: 11/AL/0163). OPDC has multi-centre research ethics approval from the South Central Oxford A Research Ethics Committee (REC reference: 16/SC/0108). AMP-PD clinical data collection and DNA samples were obtained with local institutional and ethical approvals (details can be obtained from the https://amp-pd.org and each study website). DIGPD was sponsored by Assistance Publique Hopitaux de Paris and approved by French regulatory authorities (NCT01564992). All subjects provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon request to the authors. Code used in the analysis is available online at https://github.com/huw-morris-lab/PDD_GWSS.
